Switch theme
Sign up to access all valuation multiples
United Laboratories International Holdings Ltd is mainly engaged in the research and development, production and sales of pharmaceuticals. The company operates in three segments: Intermediate products, Bulk medicine, and Finished products. The company's Finished products segment includes antibiotic products, insulin series products, and other medicines. The vast majority of the company's revenue is derived from its Bulk medicine segment, followed by Finished products. The majority of the company's sales are generated in China, followed by Europe, India and other countries.
1990
17K+
LTM Revenue $2.1B
LTM EBITDA $616M
$3.0B
Benchmark forward-looking revenue and EBITDA valuation multiples across generative AI, climate tech, semiconductors, online marketplaces, vertical SaaS and 220 more verticals.
United Laboratories International has a last 12-month revenue (LTM) of $2.1B and a last 12-month EBITDA of $616M.
In the most recent fiscal year, United Laboratories International achieved revenue of $1.8B and an EBITDA of $503M.
United Laboratories International expects next 12-month revenue of XXX and NTM EBITDA of XXX
See United Laboratories International valuation multiples based on analyst estimates| LTM | NTM | Last FY | FY 2025 | FY 2026 | FY 2027 | |
|---|---|---|---|---|---|---|
| Revenue | $2.1B | XXX | $1.8B | XXX | XXX | XXX |
| Gross Profit | $969M | XXX | $776M | XXX | XXX | XXX |
| Gross Margin | 46% | XXX | 44% | XXX | XXX | XXX |
| EBITDA | $616M | XXX | $503M | XXX | XXX | XXX |
| EBITDA Margin | 29% | XXX | 29% | XXX | XXX | XXX |
| EBIT | $520M | XXX | $398M | XXX | XXX | XXX |
| EBIT Margin | 24% | XXX | 23% | XXX | XXX | XXX |
| Net Profit | $441M | XXX | $339M | XXX | XXX | XXX |
| Net Margin | 21% | XXX | 19% | XXX | XXX | XXX |
| Net Debt | XXX | XXX | n/a | XXX | XXX | XXX |
Financial data powered by Morningstar, Inc.
As of May 30, 2025, United Laboratories International's stock price is HKD 15 (or $2).
United Laboratories International has current market cap of HKD 26.6B (or $3.4B), and EV of HKD 23.1B (or $3.0B).
See United Laboratories International trading valuation data| EV | Market Cap | Price 1D | Price 1M | Price 3M | Price 12M | EPS |
|---|---|---|---|---|---|---|
| $3.0B | $3.4B | XXX | XXX | XXX | XXX | $0.22 |
Sign up to access valuation multiples like growth-adjusted P/E, next 12-month EV/Revenue, EBITDA multiples by industry and many more
Start Free TrialAs of May 30, 2025, United Laboratories International has market cap of $3.4B and EV of $3.0B.
United Laboratories International's trades at 1.7x EV/Revenue multiple, and 5.9x EV/EBITDA.
Equity research analysts estimate United Laboratories International's 2025E EV/Revenue multiple at XXX and 2025E EV/EBITDA multiple at XXX
United Laboratories International has a P/E ratio of 8.4x.
See valuation multiples for United Laboratories International and 12K+ public comps| LTM | NTM | Last FY | FY 2025 | FY 2026 | FY 2027 | |
|---|---|---|---|---|---|---|
| Market cap (current) | $3.4B | XXX | $3.4B | XXX | XXX | XXX |
| EV (current) | $3.0B | XXX | $3.0B | XXX | XXX | XXX |
| EV/Revenue | 1.5x | XXX | 1.7x | XXX | XXX | XXX |
| EV/EBITDA | 5.2x | XXX | 5.9x | XXX | XXX | XXX |
| EV/EBIT | 6.2x | XXX | 7.4x | XXX | XXX | XXX |
| EV/Gross Profit | 3.3x | XXX | n/a | XXX | XXX | XXX |
| P/E | 8.4x | XXX | 10.0x | XXX | XXX | XXX |
| EV/FCF | n/a | XXX | 17.4x | XXX | XXX | XXX |
Valuation data powered by FactSet, Inc. and Morningstar, Inc.
Access all public comps and forward-looking valuation multiples like EV/Revenue in 2025, based on equity research analyst estimates.
Start Free TrialUnited Laboratories International's last 12 month revenue growth is 6%
United Laboratories International's revenue per employee in the last FY averaged $0.1M, while opex per employee averaged $22K for the same period.
United Laboratories International's rule of 40 is 35% (metric relevant for SaaS companies only, counted as combined revenue growth rate and EBITDA margin).
United Laboratories International's rule of X is 44% (created by Bessemer, rule of X is another metric relevant for SaaS companies only, ~1.5x stronger vs. the traditional Rule of 40, counted as revenue growth rate multiplied by 2.5 plus EBITDA margin).
See operational valuation multiples for United Laboratories International and other 12K+ public comps| LTM | NTM | Last FY | FY 2025 | FY 2026 | FY 2027 | |
|---|---|---|---|---|---|---|
| Revenue Growth | 6% | XXX | 9% | XXX | XXX | XXX |
| EBITDA Margin | 29% | XXX | 29% | XXX | XXX | XXX |
| EBITDA Growth | 9% | XXX | 13% | XXX | XXX | XXX |
| Rule of 40 | 35% | XXX | 34% | XXX | XXX | XXX |
| Bessemer Rule of X | XXX | XXX | 44% | XXX | XXX | XXX |
| Revenue per Employee | XXX | XXX | $0.1M | XXX | XXX | XXX |
| Opex per Employee | XXX | XXX | $22K | XXX | XXX | XXX |
| S&M Expenses to Revenue | XXX | XXX | 10% | XXX | XXX | XXX |
| G&A Expenses to Revenue | XXX | XXX | n/a | XXX | XXX | XXX |
| R&D Expenses to Revenue | XXX | XXX | 6% | XXX | XXX | XXX |
| Opex to Revenue | XXX | XXX | 22% | XXX | XXX | XXX |
Valuation data powered by FactSet, Inc. and Morningstar, Inc.
Benchmark public comps and private revenue and EBITDA valuation multiples across GRC software, cloud infrastructure, DevOps, online marketplaces and so much more!
| EV/Revenue | EV/EBITDA | |||||
|---|---|---|---|---|---|---|
| 2025E | 2026E | 2027E | 2025E | 2026E | 2027E | |
| Julphar | XXX | XXX | XXX | XXX | XXX | XXX |
| Benevolent AI | XXX | XXX | XXX | XXX | XXX | XXX |
| Galapagos | XXX | XXX | XXX | XXX | XXX | XXX |
| Pharming | XXX | XXX | XXX | XXX | XXX | XXX |
| Vivoryon Therapeutics | XXX | XXX | XXX | XXX | XXX | XXX |
| XXXXXXXX | XXX | XXX | XXX | XXX | XXX | XXX |
| XXXXXXXX | XXX | XXX | XXX | XXX | XXX | XXX |
Valuation data powered by FactSet, Inc.
United Laboratories International acquired XXX companies to date.
Last acquisition by United Laboratories International was XXXXXXXX, XXXXX XXXXX XXXXXX . United Laboratories International acquired XXXXXXXX for XXX (EV/Revenue multiple of XXX ).
See M&A valuation multiples| Acquired Company | EV | EV/Revenue | EV/EBITDA |
|---|---|---|---|
| XXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXX | XXX | XXX | XXX |
Sign up to see revenue and EBITDA valuation multiples for 60K+ M&A deals.
Start Free Trial| When was United Laboratories International founded? | United Laboratories International was founded in 1990. |
| Where is United Laboratories International headquartered? | United Laboratories International is headquartered in Hong Kong. |
| How many employees does United Laboratories International have? | As of today, United Laboratories International has 17K+ employees. |
| Is United Laboratories International publicy listed? | Yes, United Laboratories International is a public company listed on HKG. |
| What is the stock symbol of United Laboratories International? | United Laboratories International trades under 03933 ticker. |
| When did United Laboratories International go public? | United Laboratories International went public in 2007. |
| Who are competitors of United Laboratories International? | Similar companies to United Laboratories International include e.g. Julphar, Benevolent AI, Galapagos, Pharming. |
| What is the current market cap of United Laboratories International? | United Laboratories International's current market cap is $3.4B |
| What is the current revenue of United Laboratories International? | United Laboratories International's last 12 months revenue is $2.1B. |
| What is the current revenue growth of United Laboratories International? | United Laboratories International revenue growth (NTM/LTM) is 6%. |
| What is the current EV/Revenue multiple of United Laboratories International? | Current revenue multiple of United Laboratories International is 1.5x. |
| Is United Laboratories International profitable? | Yes, United Laboratories International is EBITDA-positive (as of the last 12 months). |
| What is the current EBITDA of United Laboratories International? | United Laboratories International's last 12 months EBITDA is $616M. |
| What is United Laboratories International's EBITDA margin? | United Laboratories International's last 12 months EBITDA margin is 29%. |
| What is the current EV/EBITDA multiple of United Laboratories International? | Current EBITDA multiple of United Laboratories International is 5.2x. |
Get access to always up-to-date, precisely categorized 70K+ public and private valuation multiples, across tech and beyond.
